Vasodilation in systemic sclerosis
Most VVD in clinical trials have been shown to exert anti-fibrotic effects – but findings are mixed around whether they also improve pulmonary function tests and prevent progression of SSc-associated interstitial lung disease (ILD). A post-hoc analysis presented by Adela-Cristina Sarbu aimed to address this by assessing the impact of VVD on functional progression and all-cause mortality in people with SSc-ILD. Using data from the EUSTAR database, they looked at three different outcomes for 2,156 people receiving endothelin-receptor antagonists (ERA), phosphodiesterase-5 ...